The journey of a novel bioconjugate into clinic is complex and uncertain. In this webinar, we explore the particular challenges when moving a bioconjugate candidate from early development into clinic. Our experts will share key considerations for de-risking this journey. From navigating the diverse conjugation technology landscape to designing a robust and scalable process through development. Several customer case studies will illustrate how Lonza’s expertise and integrated solutions have helped drug developers to bring their innovative therapeutics to life

Author: Sandro Holzer, Head of Process Development Bioconjugates, Lonza; Raphael Frey, Senior Scientist Bioconjugates, Lonza


Content Type: Webinar (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center

Whitepaper/Executive Summary
Maximizing the value of early phase material: match your development and manufacturing path to your...
Reaching IND is a major milestone. But, the journey is complex, resource-intensive and...
Lonza Bend Inhalation Lab
Peer-reviewed publication
On the Physical Stability of Leucine-Containing Spray-Dried Powders for Respiratory Drug Delivery
Carrier-free spray-dried dispersions for pulmonary delivery, for which the demand is growing,...
Whitepaper/Executive Summary
Overcome Expression Challenges of New Molecular Formats with Optimized Mammalian Technologies
Lonza's mammalian expression technologies offer commercially viable systems that cover the diversity...
Elution image - blog
Blog post
Harnessing the Power of Peptide Mapping for AAV and Adenovirus based Gene Therapy
As gene therapy developers strive to optimize their products, peptide mapping has emerged as an...
Bend-closer look
Blog post
How CDMOs Can Help Small Biotechs Meet Timeline Goals for Their Product Pipeline
The right integrated CDMO can help a small biotech company move a project into and through the...
Technical/Service brief
Brochure: mRNA/LNP Development and Manufacturing Services
Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable...
Whitepaper/Executive Summary
Current and Emerging Technologies to Optimize mRNA Manufacturing
Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable...
Sustainability webinar
Webinar (on-demand)
Environmental Sustainability at Lonza Small Molecules - Wastewater Incineration Reduction
Sustainability is at the forefront of the way Lonza runs its business. Thanks to its Vision Zero...
Small-Molecules_Drug-Product-Catalog
Presentation (on-demand)
Amorphous Solid Dispersions for Delivery of Highly Performing Formulations of Oral Oncology...
Oncology compounds are prevalent in pharmaceutical pipelines but many are poorly water soluble in...
Webinar (on-demand)
The Challenges of moving a Bioconjugate Candidate from Clinic to Market
The path to market of a novel drug is complex and uncertain. Under the growing pressure of...
Slough, United Kingdom – Small-scale manufacturing
Blog post
Product Attribute Control and Its’ role in Quality by Design
An overriding mission at Lonza, and for many CDMOs, is to consistently create effective, safe, and...
Webinar (on-demand)
From Early Development into Clinic - De-risking a Bioconjugates journey
The journey of a novel bioconjugate into clinic is complex and uncertain. In this webinar, we...